Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL\u2011CEBPA in Combination with Sorafenib in Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2020","url1":"","url2":"","graph1":"Endocrinology","graph2":"Undisclosed"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Servier","pharmaFlowCategory":"D","amount":"$262.2 million","upfrontCash":"Undisclosed","newsHeadline":"Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,250.0 million","upfrontCash":"$25.0 million","newsHeadline":"Lilly and MiNA Therapeutics Announce saRNA Research Collaboration","therapeuticArea":"Technology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Technology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$15.0 million","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Announces Equity Investment from Lilly","therapeuticArea":"Endocrinology","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Endocrinology","graph2":"Discovery Platform"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Mina Therapeutics","sponsor":"Nippon Shinyaku","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Discovery Platform","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by Mina Therapeutics

    Menu

    Mina Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Mina Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MiNA Therapeutics Enters Research Collaboration with Nippon Shinyaku to Develop RNAa Therapeutics Targeting Rare Neurodegenerative Diseases

              Details:

              Under the collaboration, MiNA Therapeutics will utilize its proprietary RNAa algorithm and technology platform to identify and characterise RNAa molecules targeting rare genetic diseases of the central nervous system (CNS).

              Lead Product(s): RNAa-based Therapy

              Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Nippon Shinyaku

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 04, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mina Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              First Patient Dosed in Randomised Phase 2 Clinical Trial of MTL-CEBPA in Patients with Advanced Liver Cancer

              Details:

              OUTREACH-2 study evaluating MTL-CEBPA specifically up-regulates CCAAT/enhancer-binding protein alpha (C/EBP-α) in combination with sorafenib, in comparison to sorafenib alone, in up to 150 patients.

              Lead Product(s): MTL-CEBPA,Sorafenib

              Therapeutic Area: Oncology Product Name: MTL-CEBPA

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Bayer AG

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable January 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mina Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MiNA Therapeutics Announces Equity Investment from Lilly

              Details:

              Proceeds from the equity investment will be used to advance and expand MiNA’s internal pipeline of saRNA therapeutics, which is initially focused on immuno-oncology and genetic diseases.

              Lead Product(s): RNA-based Medicines

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $15.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement July 06, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mina Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lilly and MiNA Therapeutics Announce saRNA Research Collaboration

              Details:

              MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly’s key therapeutic focus areas. Lilly will conduct preclinical and clinical activities of candidates and will retain commercialization rights.

              Lead Product(s): RNA-based Medicine

              Therapeutic Area: Technology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Eli Lilly

              Deal Size: $1,250.0 million Upfront Cash: $25.0 million

              Deal Type: Collaboration May 11, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mina Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MiNA Therapeutics Presents Translational Data at AACR Supporting MTL-CEBPA as Immunological Cancer Combination Treatment

              Details:

              MTL-CEBPA is the first candidate from MiNA’s pipeline of small activating RNA therapeutics. In pre-clinical studies, MTL-CEBPA was shown to counteract a key cancer immune evasion pathway by inhibiting immune suppression by myeloid cells.

              Lead Product(s): MTL-CEBPA,Pembrolizumab

              Therapeutic Area: Oncology Product Name: MTL-CEBPA

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable April 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mina Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Servier and MiNA Therapeutics Enter Collaboration in Neurological Diseases

              Details:

              As part of the collaboration, MiNA Therapeutics will use its saRNA platform to identify new potential treatments to restore normal cell function in neurological disorders.

              Lead Product(s): saRNA therapies

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Large molecule

              Partner/Sponsor/Collaborator: Servier

              Deal Size: $262.2 million Upfront Cash: Undisclosed

              Deal Type: Collaboration January 21, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mina Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MiNA Therapeutics Presents Top Line Results from Phase Ib Study of MTL‑CEBPA in Combination with Sorafenib in Liver Cancer

              Details:

              Observed clinical activity, including durable and complete tumour responses, suggests that MTL-CEBPA may increase the effectiveness of sorafenib standard of care.

              Lead Product(s): MTL-CEBPA,Sorafenib

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 29, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mina Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MiNA Therapeutics Announces Initiation of Phase I Clinical Study of MTL-CEBPA

              Details:

              The study is designed to assess the safety, tolerability, pharmacology and clinical activity of MTL-CEBPA in combination with pembrolizumab in these patients.

              Lead Product(s): MTL-CEBPA,Pembrolizumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase I Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 03, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Mina Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MiNA Therapeutics Announces Research Collaboration with AstraZeneca in Metabolic Diseases

              Details:

              The collaboration combines MiNA's expertise in the discovery & development of saRNA therapeutics with AstraZeneca's experience in bringing breakthrough treatments to patients with metabolic diseases.

              Lead Product(s): saRNA

              Therapeutic Area: Endocrinology Product Name: Undisclosed

              Highest Development Status: Undisclosed Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: AstraZeneca

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration January 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY